article thumbnail

The continued shame of pharma

World of DTC Marketing

Late last year, the Senate Finance Committee released draft legislation enabling Medicare negotiation for up to 10 drugs in 2025, 15 in 2026 and 2027, and 20 in 2028 and beyond. This would include drugs covered by both Medicare Part B (physician-administered drugs) and Part D (prescription medications). The secretary of the U.S.

Pharma 256
article thumbnail

American healthcare is too profitable

World of DTC Marketing

healthcare system is bedeviled by greed, with drug companies, device manufacturers, hospital organizations, physician groups, and insurers scrambling to grab a slice of the more than $3 trillion we spend on medical care each year. (FT.COM) The U.S. We have access to the most cutting-edge treatments. That’s about $375 per month.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Amgen commits $8m to clinical trial diversity programme

European Pharmaceutical Review

The contribution will enable the programme to reach additional physicians and medical students, further expanding the initiative that aims to extend the reach of clinical trials in underserved patient populations in US communities. The Winn Award Program has so far trained 114 early-stage investigator physicians.

article thumbnail

Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m

European Pharmaceutical Review

Nebido is also patented until March 2024 in the European Union and until May 2027 in the United States. The long-acting injectable treatment for testosterone deficiency has been commercially approved in more than 80 countries.

article thumbnail

CD19 CAR-T agents to boost blood cancer market

European Pharmaceutical Review

Breyanzi sales will also be supplemented by the anticipated approval in chronic lymphocytic leukemia (CLL) in 2027, making it the first and only currently marketed CD19 CAR-T agent to penetrate the CLL market. Breyanzi will exhibit the largest compound annual growth rate (CAGR) at 30 percent, compared to Yescarta’s CAGR of 9 percent.

article thumbnail

Consequences of the First 10 Drugs Selected for Medicare’s Negotiation Program

PM360

After this period, CMS will begin to include physician-administered drugs covered under Part B in the program. The IRA sets physician reimbursement of these products at the CMS-established MFP plus 6% versus current average sales price.

article thumbnail

The Top 10 Clinical Research Companies in the USA

Medico Reach

billion , and by 2027, it is expected to reach around an exciting amount of 115.1 from 2022 to 2027. Moreover, its services are spread through care organizations, hospitals, government agencies, pharmaceutical companies, and physicians. In 2022, the global clinical research market stands at $63.6 billion with a CAGR of 11.0%